Objectives: Osteoarthritis (OA) is the most common and costly bone and joint disease in the elderly. Recently, viscosupplementation, an intra-articular injection of artificial joint fluid in order to restore rheological properties affecting lubrication and shock absorption, has introduced as an alternative conservative treatment. To assess the effectiveness and cost-effectiveness of Hylan G-F 20 (Hylan) as a substitute for existing treatments for pain due to OA of the knee, other viscosupplementation devices, and/or as an adjunct to conventional therapy. MethOds: A Markov microsimulation model was developed to define a treatment pathway for OA of the knee, illustrate the current costs of treating patients with the condition, and demonstrate the potential savings associated with introduction of Hylan. A hypothetical cohort of patients categorized as having 2-3 or 4 degree of OA of the knee was followed over a 30-month time period. Results: When comparing intra-articular administration of Hylan, the use of NSAIDs and intra-articular administration of corticosteroids (GCS), rirost costs compared with the strategy of NSAIDs amounted to $192 rate per 1 patient. This increase in efficiency of 20% in favor of Hylan. Accordingly, the ratio ICER was $979 per patient, which is much below the threshold of "society's willingness to pay." Markov cycle for patients with OA of the knee of 4 degrees showed that use of Hylan is more effective in the end point of modeling the effectiveness of this strategy was 12% (compared to 0% in the policies of NSAIDs and corticosteroids). We calculated the total cost of the budget in the application of NSAIDs, GCS, and Hylan, after calculations found that the use of Gilan can save significant budget funds -up to $954582 (for 1,000 patients). cOnclusiOns: Hylan may delay the need for joint replacement in patients with OA of 4 degrees, suggest its use is justified from a clinical and economic standpoint as compared to the consideration of other treatment strategies. Objectives: Failed back surgery syndrome (FBSS) represents one main cause of chronic neuropathic or mixed pain and functional disability. Results from previous clinical trials and from the PRECISE naturalistic study [Zucco et al, Neuromodulation, 2015] show that Spinal Cord Stimulation (SCS) provides pain relief and improves patients' health. Our current aim is to understand the relationship between pain intensity, functional disability, and overall Health-Related Quality-of-life (HRQoL). MethOds: At recruitment (before SCS) and every 6 months for 2 years after SCS a battery of questionnaires/tests were completed: EQ-5D-3L and SF-36 for HRQoL, the Numerical Rating Scale (NRS) to measure pain intensity, and the Oswestry Disability Index (ODI) to measure disability/functional capability. Statistical tests were conducted to compare the HRQoL levels (using the EQ-5D utility index, the EQ-VAS, the SF-36 Physical Component Summary (PCS) and Mental Component Summary (MCS) index), NRS and ODI at baseline with those measured during the observational period. Multilevel regression analyses were conducted to investigate the association between the HRQOL indexes and the NRS and ODI indexes, on adjusting for: age, gender, previous surgery, education, baseline level of the dependent variable, and time of assessment. Results: Eighty patients (40% male, mean age= 58 years) participated. Significant improvements (p< 0.001) in pain intensity, functional capability and HRQoL were reached after 6 months from SCS and maintained or further improved until the end of the observational period. According to the regression models, every HRQoL index was significantly associated (p< 0.001) with both the NRS and the ODI indexes at any time of assessment. cOnclusiOns: Our results suggest that in a 2-year observational period, SCS+CMM treatment reduces significantly pain intensity and functional disability in patients with FBSS, with significant repercussions on their general HRQOL. Furthermore, our results suggest the HRQoL instruments used in this study are valid to assess overall patients' health and treatment outcomes. Objectives: Effective but expensive (approximately € 14,000 per year) tumor necrosis factor inhibiting drugs (TNFi) are used for the treatment of several chronic inflammatory diseases including rheumatoid arthritis (RA). A proven dose reduction strategy in RA patients could result in substantial cost savings. It may however also lead to a loss of quality of life as a result of flares induced by dose reduction attempts. If this loss is compensated with large cost saving, we might still consider the intervention cost-effective. MethOds: a pre-planned cost-effectiveness analysis of the DRESS study, a randomised controlled, non-inferiority trial comparing a disease activity guided dose optimisation strategy with usual care in patients with RA and low disease activity using TNFi. Total health care costs were measured and quality adjusted life years (QALY) were based on EQ5d utilities. Decremental costeffectiveness ratio and incremental net monetary benefit (iNMB) were determined. of the Psoriatic Arthritis Response Criteria, Health Assessment Questionnaire and Psoriasis Area and Severity Index data, synthesized from published clinical trials via a Bayesian network meta-analysis. Following a payer perspective, direct costs relating to drug acquisition, administration, monitoring and overall patient management were considered (2015). Results: All anti-TNF therapies yielded greater improvements in the aforementioned efficacy outcomes and in terms of quality-adjusted life years (QALYs) compared to SoC. The incremental cost per QALY gained of CZP relative to SoC was € 16,539 and € 20,714 at 12-and 24-week response assessment period respectively, which is below the established willingness-to-pay threshold of € 34,000. Between the anti-TNFs, efficacy differences did not reach statistical significance. In terms of the mean lifetime patient cost, it ranged from € 61,469 for CZP to € 86,632 for infliximab, assuming a 12-week response assessment period. Similarly, at the alternative assessment period scenario, it ranged from € 66,401 and € 67,499 for golimumab and CZP respectively, to € 83,483 for infliximab. cOnclusiOns: CZP was found to be cost-effective relative to SoC and as effective in terms of efficacy and less costly, i.e. dominant, compared to most other licensed anti-TNF agents in Greece.
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PMS75 teleRehabilitation aFteR total knee RePlaceMent: PReliMinaRy coSt-eFFectiveneSS analySiS oF an innovative Device
Fusco F 1 , Turchetti G 2 1 Scuola Superiore Sant'Anna, Pisa, Italy, 2 Scuola Superiore Sant 'Anna, Pisa, Italy Objectives: A Telerehabilitation service following Total Knee Replacement (TKR) has been shown to be not inferior to standard rehabilitation (SR) in recovering the active knee flexion range of motion (ROM) in patients who had not complication related to TKR surgery. However, little is known about its cost-effectiveness. The objective of this economic evaluation was to assess cost-effectiveness of telerehabilitation versus SR. MethOds: A Markov model was employed to simulate the natural progression of TKR, assuming telerehabilitation does not influence this. The revision risk was calculated from patient-level data (multicentre KAT trial) employing a parametric model including established prognostic factors. The others state-transition probabilities and treatments effects were obtained from published literature. Rehabilitation and transportation costs were assessed adopting Ita-NHS perspective employing Italian tariffs. The patients without complications followed the TR-SR programme receiving half of the sessions in SR and half in telerehabilitation regime. Patients with any complication followed the SR receiving face-to-face sessions. Results were adjusted applying an annual discount rate of 3% and half-cycle correction. Probabilistic sensitivity analysis (PSA) described the parameters uncertainty. Results: A cohort of 1000 patients with the features of KAT trial population (70 years old, 44% male and 19% had any complication related to the surgery) were first assigned to SR then to TR -SR. The mean (SE) lifetime healthcare cost in SR arm were € 1,033.81 (€ 21.97) and € 818.44 (€ 13.82) for telerehabilitation (mean±95%CI difference -215.33±€ 10.64). Mean (SE) ROM was 16.68 (0.04) in SR programme and 18.84 (0.04) in telerehabilitation programme (mean±95%CI difference 2.16±0.09). The probability that telerehabilitation is costsaving (WTP:€ 0) is 92%. cOnclusiOns: Adopting the healthcare provider perspective, TR-SR seems cost-effective when compared to a SR programme. Further sensitivity analyses are required to relax the model assumptions and to assess the robustness of the model.
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